Skip to main content
Clinical Trials/NCT06590233
NCT06590233
Completed
Not Applicable

The Risk Factors and Predictors of Hyperglycemia Secondary to Acute Pancreatitis

Shanghai Changzheng Hospital0 sites4,500 target enrollmentJanuary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Pancreatitis (AP)
Sponsor
Shanghai Changzheng Hospital
Enrollment
4500
Primary Endpoint
Number of participants who have developed PPDM-A
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this observational study is to learn about post-acute pancreatitis diabetes mellitus (PPDM-A). The main questions it aims to answer are:

  1. What are the clinical characteristics of PPDM-A?
  2. What are the related factors for PPDM-A?

All patients with acute pancreatitis have been given standardized treatment for the condition.

The researchers will compare the PPDM-A group with the non-PPDM-A group to find the risk factors for PPDM-A.

Detailed Description

Investigators retrospectively collected data from patients with acute pancreatitis (AP) in participating centers between January 2013 and June 2024.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
August 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Tuo Li, MD

Deputy Director

Shanghai Changzheng Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients with pancreatitis attending participating centers since January 2013 (patients with clinically reported AP (ICD-10:K85 or related diagnosis));
  • Age between 18 and 80 years;
  • Patients have undergone glucose metabolic tests at least 1 month after discharge from hospital.

Exclusion Criteria

  • Patients with a history of diabetes mellitus prior to the AP attack;
  • Patients who underwent pancreatic surgery;
  • Patients with hereditary pancreatitis and autoimmune pancreatitis;
  • Patients with missing data regarding age or gender.

Outcomes

Primary Outcomes

Number of participants who have developed PPDM-A

Time Frame: From the AP treatment to 5 years after the end of treatment

PPDM-A was defined as diabetes after AP in the absence of a history of preexisting diabetes before the AP episode.

Similar Trials